Sec Form 13G Filing - AbbVie Biotechnology Ltd. filing for Carisma Therapeutics, Inc. (CARM) - 2025-04-25

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The reported percentage is calculated based upon 41,788,096 shares of Common Stock outstanding as of March 26, 2025, as reported in the Issuer's annual report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 31, 2025.


SCHEDULE 13G


 
AbbVie Biotechnology Ltd.
 
Signature:/s/ Arthur C. Price
Name/Title:Arthur C. Price/Director
Date:04/25/2025
primary_doc.xml